Published in Leukemia on January 23, 2017
Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell (1994) 5.79
The molecular biology of chronic myeloid leukemia. Blood (2000) 5.22
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (1990) 5.20
2016 update of the PRIDE database and its related tools. Nucleic Acids Res (2015) 5.14
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer (2005) 4.30
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med (1999) 4.06
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet (2004) 3.96
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst (2011) 3.51
An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nat Methods (2006) 3.38
Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol (2004) 3.10
The BCR-ABL story: bench to bedside and back. Annu Rev Immunol (2004) 3.00
Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer (2012) 2.35
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med (2004) 2.23
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst (2008) 2.21
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood (2011) 2.08
Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol (2007) 1.88
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol (2012) 1.77
Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia (2009) 1.70
A phosphatase activity of Sts-1 contributes to the suppression of TCR signaling. Mol Cell (2007) 1.43
Rapid and reproducible single-stage phosphopeptide enrichment of complex peptide mixtures: application to general and phosphotyrosine-specific phosphoproteomics experiments. Anal Chem (2011) 1.40
Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci U S A (2009) 1.37
Structure of the unphosphorylated STAT5a dimer. J Biol Chem (2005) 1.32
Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. Nat Methods (2013) 1.30
How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (2010) 1.25
Studying the pathogenesis of BCR-ABL+ leukemia in mice. Oncogene (2002) 1.22
Monoclonal antibodies specific for v-abl- and c-abl-encoded molecules. J Virol (1986) 1.21
Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl. Mol Cell (2005) 1.21
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene (1996) 1.19
The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood (1995) 1.15
BioID: a screen for protein-protein interactions. Curr Protoc Protein Sci (2013) 1.14
Modeling Philadelphia chromosome positive leukemias. Oncogene (2001) 1.04
K562 leukemia cells transfected with the human c-fes gene acquire the ability to undergo myeloid differentiation. J Biol Chem (1989) 1.03
Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. Leukemia (2008) 1.00
Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. Sci Signal (2011) 0.99
The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization. Oncogene (2010) 0.98
Structure, regulation, signaling, and targeting of abl kinases in cancer. Genes Cancer (2012) 0.90
Diverging fates of cells of origin in acute and chronic leukaemia. EMBO Mol Med (2012) 0.86
Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants. Blood (2000) 0.86
Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. Blood (2003) 0.85
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood (2016) 0.84
Meet the neighbors: Mapping local protein interactomes by proximity-dependent labeling with BioID. Proteomics (2016) 0.82
Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis. Leukemia (2017) 0.77
Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization. Sci Rep (2016) 0.75